VCAN and breast cancer: We also analyzed 7 breast cancer cases (3 from Group 2/nulliparous women, 2 from Group 3/early pregnancy and 2 from Group 5/late pregnancy) with immunohistochemistry against PR, Versican, Wnt4, CD15 and β-Catenin.